Feb. 15 at 1:57 PM
$CTMX If the expansion study holds up and confirms those previously reported ORR and mPFS numbers in the 70-100-patient cohorts with some dosage regimen, Varseta-M would look a lot less risky. At that point, the asset becomes strategically very compelling. it’s hard to imagine big pharma ignoring the size of the market it could potentially address. The odds of a takeout would increase meaningfully, similar to what we saw with VTYX.
I still kick myself for dumping all my VTYX shares for a ~600% gain the night it spiked to
$7–8 on the data drop. Only a few months later, it was acquired at
$14. This time, if the data come in clean and strong, I plan to hang on to at least a chunk of it for longer instead of selling all into the initial pop. Fingers crossed.
